CoChat
Sign Up
Cited by 131Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolismIron Metabolism and Disorders

Iron and Oxidative Stress in Parkinson’s Disease: An Observational Study of Injury Biomarkers

Open access
Medeiros, Marcio S., Schumacher-Schuh, Arthur, Cardoso, Andreia Machado, Bochi, Guilherme Vargas, Baldissarelli, Jucimara, Kegler, Aline, Santana, Daniel, Chaves, Carolina Maria Martins Behle Soares +4 more·2016·PLOS ONE
DOI 10.1371/journal.pone.0146129PMC PMC4709097
Open this paper in CoChat — free accountOpen PDF

Abstract

Parkinson's disease (PD) is characterized by progressive motor impairment attributed to progressive loss of dopaminergic neurons in the substantia nigra (SN) pars compacta. In addition to an accumulation of iron, there is also an increased production of reactive oxygen/nitrogen species (ROS/RNS) and inflammatory markers. These observations suggest that iron dyshomeostasis may be playing a key role in neurodegeneration. However, the mechanisms underlying this metal-associated oxidative stress and neuronal damage have not been fully elucidated. To determine peripheral levels of iron, ferritin, and transferrin in PD patients and its possible relation with oxidative/nitrosative parameters, whilst attempting to identify a profile of peripheral biomarkers in this neurological condition. Forty PD patients and 46 controls were recruited to compare serum levels of iron, ferritin, transferrin, oxidative stress markers (superoxide dismutase (SOD), catalase (CAT), nitrosative stress marker (NOx), thiobarbituric acid reactive substances (TBARS), non-protein thiols (NPSH), advanced oxidation protein products (AOPP), ferric reducing ability of plasma (FRAP) and vitamin C) as well as inflammatory markers (NTPDases, ecto-5'-nucleotidase, adenosine deaminase (ADA), ischemic-modified albumin (IMA) and myeloperoxidase). Iron levels were lower in PD patients, whereas there was no difference in ferritin and transferrin. Oxidative stress (TBARS and AOPP) and inflammatory markers (NTPDases, IMA, and myeloperoxidase) were significantly higher in PD, while antioxidants FRAP, vitamin C, and non-protein thiols were significantly lower in PD. The enzymes SOD, CAT, and ecto-5'-nucleotidase were not different among the groups, although NOx and ADA levels were significantly higher in the controls. Our data corroborate the idea that ROS/RNS production and neuroinflammation may dysregulate iron homeostasis and collaborate to reduce the periphery levels of this ion, contributing to alterations observed in the pathophysiology of PD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0146129

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 61

  1. [1]Dai DF, Chiao YA, Marcinek DJ, Szeto HH, Rabinovitch PS. Mitochondrial oxidative stress in aging and healthspan. Longevity & healthspan. 2014; 3: 6. Pubmed Central PMCID: 4013820. 24860647 PMC4013820
  2. [2]Perfeito R, Cunha-Oliveira T, Rego AC. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease—resemblance to the effect of amphetamine drugs of abuse. Free radical biology & medicine. 2012 11 1; 53(9): 1791– 806.. 22967820
  3. [3]Savica R, Grossardt BR, Carlin JM, Icen M, Bower JH, Ahlskog JE, et al Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. Neurology. 2009 10 27; 73(17): 1381– 7. Pubmed Central PMCID: 2769554. 10.1212/WNL.0b013e3181bd80c1 19858460 PMC2769554 · DOI · Paper page
  4. [5]Vinish M, Anand A, Prabhakar S. Altered oxidative stress levels in Indian Parkinson's disease patients with PARK2 mutations. Acta biochimica Polonica. 2011; 58(2): 165– 9.. 21584286
  5. [8]Lipschitz DA. Screening for nutritional status in the elderly. Primary care. 1994 3; 21(1): 55– 67.. 8197257
  6. [9]Hanasand M, Omdal R, Norheim KB, Goransson LG, Brede C, Jonsson G. Improved detection of advanced oxidation protein products in plasma. Clinica chimica acta; international journal of clinical chemistry. 2012 5 18; 413(9–10): 901– 6. 10.1016/j.cca.2012.01.038 22336637 · DOI
  7. [10]Kaefer M, Piva SJ, De Carvalho JA, Da Silva DB, Becker AM, Coelho AC, et al Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clinical biochemistry. 2010 3; 43(4–5): 450– 4. 10.1016/j.clinbiochem.2009.11.018 19968982 · DOI
  8. [11]Tatsch E, Bochi GV, Pereira Rda S, Kober H, Agertt VA, de Campos MM, et al A simple and inexpensive automated technique for measurement of serum nitrite/nitrate. Clinical biochemistry. 2011 3; 44(4): 348– 50. 10.1016/j.clinbiochem.2010.12.011 21185277 · DOI
  9. [12]Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Analytical biochemistry. 1996 7 15; 239(1): 70– 6.. 8660627
  10. [13]Jentzsch AM, Bachmann H, Furst P, Biesalski HK. Improved analysis of malondialdehyde in human body fluids. Free radical biology & medicine. 1996; 20(2): 251– 6.. 8746446
  11. [14]Ellman GL. Tissue sulfhydryl groups. Archives of biochemistry and biophysics. 1959 5; 82(1): 70– 7.. 13650640
  12. [15]Nelson DP, Kiesow LA. Enthalpy of decomposition of hydrogen peroxide by catalase at 25 degrees C (with molar extinction coefficients of H 2 O 2 solutions in the UV). Analytical biochemistry. 1972 10; 49(2): 474– 8.. 5082943
  13. [16]McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). The Journal of biological chemistry. 1969 11 25; 244(22): 6049– 55.. 5389100
  14. [17]Jacques-Silva MC, Nogueira CW, Broch LC, Flores EM, Rocha JB. Diphenyl diselenide and ascorbic acid changes deposition of selenium and ascorbic acid in liver and brain of mice. Pharmacology & toxicology. 2001 3; 88(3): 119– 25.. 11245406
  15. [18]Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry. 1976 5 7; 72: 248– 54.. 942051
  16. [19]Lunkes GI, Lunkes DS, Morsch VM, Mazzanti CM, Morsch AL, Miron VR, et al NTPDase and 5'-nucleotidase activities in rats with alloxan-induced diabetes. Diabetes research and clinical practice. 2004 7; 65(1): 1– 6.. 15163471
  17. [20]Giusti G, Gakis C. Temperature conversion factors, activation energy, relative substrate specificity and optimum pH of adenosine deaminase from human serum and tissues. Enzyme. 1971; 12(4): 417– 25.. 5316093
  18. [21]Metcalf J, Gallin JI, Nauseef WM, Root RK. Laboratory manual of neutrophil function. New York, N.Y: Raven Press; 1986 pp. 87– 94.
  19. [22]Mariani S, Ventriglia M, Simonelli I, Donno S, Bucossi S, Vernieri F, et al Fe and Cu do not differ in Parkinson's disease: a replication study plus meta-analysis. Neurobiology of aging. 2013 2; 34(2): 632– 3. 10.1016/j.neurobiolaging.2012.05.015 22738721 · DOI
  20. [23]Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, et al Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Archives of neurology. 2002 6; 59(6): 999– 1005.. 12056937
  21. [25]Weinreb O, Mandel S, Youdim MB, Amit T. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free radical biology & medicine. 2013 9; 62: 52– 64.. 23376471
  22. [26]Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, et al Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxidants & redox signaling. 2014; 21(2): 195– 210. 10.1089/ars.2013.5593 24251381 PMC4060813 · DOI
  23. [27]Madenci G, Bilen S, Arli B, Saka M, Ak F. Serum iron, vitamin B12 and folic acid levels in Parkinson's disease. Neurochemical research. 2012 7; 37(7): 1436– 41. 10.1007/s11064-012-0729-x 22367474 · DOI
  24. [28]Friedman A, Arosio P, Finazzi D, Koziorowski D, Galazka-Friedman J. Ferritin as an important player in neurodegeneration. Parkinsonism & related disorders. 2011 7; 17(6): 423– 30.. 21550835
  25. [29]Ayton S, Faux NG, Bush AI, Alzheimer's Disease Neuroimaging I. Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nature communications. 2015; 6: 6760 Pubmed Central PMCID: 4479012. 10.1038/ncomms7760 25988319 PMC4479012 · DOI
  26. [30]Jaffrey SR, Cohen NA, Rouault TA, Klausner RD, Snyder SH. The iron-responsive element binding protein: a target for synaptic actions of nitric oxide. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91(26): 12994– 8. 7809162 PMC45567
  27. [31]Ayton S, Lei P, Hare DJ, Duce JA, George JL, Adlard PA, et al Parkinson's disease iron deposition caused by nitric oxide-induced loss of beta-amyloid precursor protein. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2015; 35(8): 3591– 7. 10.1523/JNEUROSCI.3439-14.2015. 25716857 PMC6605561 · DOI
  28. [32]Tuncel D, Inanc Tolun F, Toru I. Serum insulin-like growth factor-1 and nitric oxide levels in Parkinson's disease. Mediators of inflammation. 2009; 2009: 132464 Pubmed Central PMCID: 2655363. 10.1155/2009/132464 19300521 PMC2655363 · DOI
  29. [33]Kavya R, Saluja R, Singh S, Dikshit M. Nitric oxide synthase regulation and diversity: implications in Parkinson's disease. Nitric oxide: biology and chemistry / official journal of the Nitric Oxide Society. 2006 12; 15(4): 280– 94.. 16934505
  30. [34]Singh S, Dikshit M. Apoptotic neuronal death in Parkinson's disease: involvement of nitric oxide. Brain research reviews. 2007 6; 54(2): 233– 50.. 17408564
  31. [35]Manukhina EB, Mashina S, Smirin BV, Lyamina NP, Senchikhin VN, Vanin AF, et al Role of nitric oxide in adaptation to hypoxia and adaptive defense. Physiological research / Academia Scientiarum Bohemoslovaca. 2000; 49(1): 89– 97.. 10805409
  32. [36]Younes-Mhenni S, Frih-Ayed M, Kerkeni A, Bost M, Chazot G. Peripheral blood markers of oxidative stress in Parkinson's disease. European neurology. 2007; 58(2): 78– 83.. 17565220
  33. [37]Shukla R, Rajani M, Srivastava N, Barthwal MK, Dikshit M. Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinson's disease. The International journal of neuroscience. 2006 12; 116(12): 1391– 402.. 17145675
  34. [38]Kouti L, Noroozian M, Akhondzadeh S, Abdollahi M, Javadi MR, Faramarzi MA, et al Nitric oxide and peroxynitrite serum levels in Parkinson's disease: correlation of oxidative stress and the severity of the disease. European review for medical and pharmacological sciences. 2013 4; 17(7): 964– 70.. 23640445
  35. [39]Kuiper MA, Visser JJ, Bergmans PL, Scheltens P, Wolters EC. Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients. Journal of the neurological sciences. 1994 1; 121(1): 46– 9.. 8133311
  36. [40]Huskic J, Paperniku A, Husic A, Alendar F, Mulabegovic N. Significantly reduced salivary nitric oxide synthesis in patients with Parkinson's disease. Bosnian journal of basic medical sciences / Udruzenje basicnih mediciniskih znanosti = Association of Basic Medical Sciences. 2005 8; 5(3): 86– 9.. 16351589 PMC7202145
  37. [41]Molina JA, Jimenez-Jimenez FJ, Navarro JA, Vargas C, Gomez P, Benito-Leon J, et al Cerebrospinal fluid nitrate levels in patients with Parkinson's disease. Acta neurologica Scandinavica. 1996 Feb-Mar; 93(2–3): 123– 6.. 8741130
  38. [42]Ricart-Jane D, Llobera M, Lopez-Tejero MD. Anticoagulants and other preanalytical factors interfere in plasma nitrate/nitrite quantification by the Griess method. Nitric oxide: biology and chemistry / official journal of the Nitric Oxide Society. 2002 3; 6(2): 178– 85.. 11890742
  39. [43]Sudha K, Rao AV, Rao S, Rao A. Free radical toxicity and antioxidants in Parkinson's disease. Neurology India. 2003 3; 51(1): 60– 2.. 12865518
  40. [44]Chtourou Y, Fetoui H, Sefi M, Trabelsi K, Barkallah M, Boudawara T, et al Silymarin, a natural antioxidant, protects cerebral cortex against manganese-induced neurotoxicity in adult rats. Biometals: an international journal on the role of metal ions in biology, biochemistry, and medicine. 2010 12; 23(6): 985– 96.. 20503066
  41. [45]Baser H, Can U, Baser S, Yerlikaya FH, Aslan U, Hidayetoglu BT. Assesment of oxidative status and its association with thyroid autoantibodies in patients with euthyroid autoimmune thyroiditis. Endocrine. 2015 4; 48(3): 916– 23. 10.1007/s12020-014-0399-3 25150037 · DOI
  42. [46]Dringen R. Metabolism and functions of glutathione in brain. Progress in neurobiology. 2000 12; 62(6): 649– 71.. 10880854
  43. [47]Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, et al Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Annals of neurology. 1994 9; 36(3): 348– 55.. 8080242
  44. [48]Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. The international journal of biochemistry & cell biology. 2007; 39(1): 44– 84.. 16978905
  45. [49]Desai V, Prasad NR, Manohar SM, Sachan A, Narasimha SR, Bitla AR. Oxidative stress in non-obese women with polycystic ovarian syndrome. Journal of clinical and diagnostic research: JCDR. 2014 7; 8(7): CC01– 3. Pubmed Central PMCID: 4149064. 10.7860/JCDR/2014/8125.4530 25177558 PMC4149064 · DOI
  46. [50]Pasquali L, Pecori C, Lucchesi C, LoGerfo A, Iudice A, Siciliano G, et al Plasmatic oxidative stress biomarkers in multiple sclerosis: relation with clinical and demographic characteristics. Clinical biochemistry. 2015 1; 48(1–2): 19– 23. 10.1016/j.clinbiochem.2014.09.024 25300461 · DOI
  47. [51]Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clinical chemistry. 2006 4; 52(4): 601– 23.. 16484333
  48. [53]Lenaz G. Mitochondria and reactive oxygen species. Which role in physiology and pathology? Advances in experimental medicine and biology. 2012; 942: 93– 136. 10.1007/978-94-007-2869-1_5 22399420 · DOI
  49. [54]Danielson SR, Andersen JK. Oxidative and nitrative protein modifications in Parkinson's disease. Free radical biology & medicine. 2008 5 15; 44(10): 1787– 94.. Pubmed Central PMCID: 2422863. 18395015 PMC2422863
  50. [55]Yoshida O, Kimura S, Jackson EK, Robson SC, Geller DA, Murase N, et al CD39 expression by hepatic myeloid dendritic cells attenuates inflammation in liver transplant ischemia-reperfusion injury in mice. Hepatology. 2013 12; 58(6): 2163– 75. Pubmed Central PMCID: 3844081. 10.1002/hep.26593 23813862 PMC3844081 · DOI
  51. [56]Brisevac D, Bajic A, Bjelobaba I, Milosevic M, Stojiljkovic M, Beyer C, et al Expression of ecto-nucleoside triphosphate diphosphohydrolase1-3 (NTPDase1-3) by cortical astrocytes after exposure to pro-inflammatory factors in vitro. Journal of molecular neuroscience: MN. 2013 11; 51(3): 871– 9. 10.1007/s12031-013-0088-3 23990338 · DOI
  52. [57]Spanevello RM, Mazzanti CM, Bagatini M, Correa M, Schmatz R, Stefanello N, et al Activities of the enzymes that hydrolyze adenine nucleotides in platelets from multiple sclerosis patients. Journal of neurology. 2010 1; 257(1): 24– 30. 10.1007/s00415-009-5258-4 19629564 · DOI
  53. [58]Anatoliotakis N, Deftereos S, Bouras G, Giannopoulos G, Tsounis D, Angelidis C, et al Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular disease. Current topics in medicinal chemistry. 2013; 13(2): 115– 38.. 23470074
  54. [59]Nakazato T, Sagawa M, Yamato K, Xian M, Yamamoto T, Suematsu M, et al Myeloperoxidase is a key regulator of oxidative stress mediated apoptosis in myeloid leukemic cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007 9 15; 13(18 Pt 1): 5436– 45.. 17875773
  55. [60]Ellidag HY, Bulbuller N, Eren E, Abusoglu S, Akgol E, Cetiner M, et al Ischemia-modified albumin: could it be a new oxidative stress biomarker for colorectal carcinoma? Gut and liver. 2013 11; 7(6): 675– 80. Pubmed Central PMCID: 3848539. 10.5009/gnl.2013.7.6.675 24312708 PMC3848539 · DOI
  56. [61]Mahajan M, Tiwari N, Sharma R, Kaur S, Singh N. Oxidative stress and its relationship with adenosine deaminase activity in various stages of breast cancer. Indian journal of clinical biochemistry: IJCB. 2013 1; 28(1): 51– 4. Pubmed Central PMCID: 3547448. 10.1007/s12291-012-0244-5 24381421 PMC3547448 · DOI
  57. [62]DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science. 2003 10 31; 302(5646): 830– 4.. 14593169
  58. [63]Gerlach M, Maetzler W, Broich K, Hampel H, Rems L, Reum T, et al Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. Journal of neural transmission. 2012 1; 119(1): 39– 52. Pubmed Central PMCID: 3250615. 10.1007/s00702-011-0682-x 21755462 PMC3250615 · DOI
  59. [64]Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain: a journal of neurology. 2010 3; 133(Pt 3): 713– 26.. Pubmed Central PMCID: 2842513. 20157014 PMC2842513
  60. [65]Han M, Nagele E, DeMarshall C, Acharya N, Nagele R. Diagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human sera. PloS one. 2012; 7(2): e32383 Pubmed Central PMCID: 3285212. 10.1371/journal.pone.0032383 22384236 PMC3285212 · DOI
  61. [66]Pare S, Barr SI, Ross SE. Effect of daytime protein restriction on nutrient intakes of free-living Parkinson's disease patients. The American journal of clinical nutrition. 1992 3; 55(3): 701– 7.. 1550046

Cited by

Sorted by citations

Authors
Medeiros, M. S., Schumacher-Schuh, A., Cardoso, A. M., Bochi, G. V., Baldissarelli, J., Kegler, A., Santana, D., Chaves, C. M. M. B. S., Schetinger, M. R. C., Moresco, R. N., Rieder, C. R. M., & Fighera, M. R.
Affiliations
Universidade Federal de Santa Maria (BR)
Corresponding author
Fighera, Michele Rechia
ORCID
Venue
PLOS ONE
Publisher
Public Library of Science (PLoS)
Published
2016-01-11
Volume
11
Issue
1
Pages
e0146129
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0146129
PMC
PMC4709097
OpenAlex
W2233096610
Cited by
131
References
4
Citations by year
2026: 6 · 2025: 7 · 2024: 7 · 2023: 16 · 2022: 12 · 2021: 16 · 2020: 15 · 2019: 12 · 2018: 18 · 2017: 19 · 2016: 3
FWCI
13.03
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (2011-9)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
Keywords
Parkinson's disease, iron dyshomeostasis, oxidative stress, nitrosative stress, neuroinflammation, peripheral biomarkers, serum iron, ferritin, transferrin, lipid peroxidation, advanced oxidation protein products, antioxidant capacity, ischemia-modified albumin, myeloperoxidase, adenosine deaminase, dopaminergic neuron loss
MeSH terms
Adenosine Deaminase, Adenosine Triphosphatases, Aged, Ascorbic Acid, Catalase, Female, Ferritins, Humans, Iron, Male, Middle Aged, Peroxidase, Oxidation-Reduction, Parkinson Disease, Sulfhydryl Compounds, Superoxide Dismutase, Transferrin, Biomarkers, 5'-Nucleotidase, Case-Control Studies, Reactive Oxygen Species, Thiobarbituric Acid Reactive Substances, Oxidative Stress, Reactive Nitrogen Species, Dopaminergic Neurons, Advanced Oxidation Protein Products, Pars Compacta

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review